Quest Diagnostics Incorporated (DGX) Stock Price & How to Invest

Quest Diagnostics operates one of the largest clinical laboratory networks in the United States, processing billions of test results a year across a footprint of patient service centers, hospital and physician outreach relationships, and consumer-initiated testing. Its core Diagnostic Information Services segment spans routine testing (blood counts, cholesterol, metabolic panels) plus a growing base of advanced molecular and genomic diagnostics in oncology, neurology, women's health, and infectious disease. Scale, a national logistics network, and long-standing payer contracts are the company's main moats in a fragmented roughly $100 billion US lab market where Quest and Labcorp together hold the top tier.

The investment picture is that of a defensive healthcare-services business trading at a moderate valuation, with growth coming from organic volume, a steady cadence of tuck-in lab acquisitions, and a mix shift toward higher-value advanced testing. Q1 2026 showed revenue up about 9 percent and adjusted EPS up double digits, prompting raised full-year guidance. The offsetting concern is reimbursement policy: Medicare rate schedules under PAMA and broader payer pressure cap pricing power, so the bull case rests on volume, efficiency (including AI and automation), and acquisitions rather than price increases.

The largest risk is reimbursement policy: Medicare rates under PAMA face potential cuts (a delay pushed reductions toward 2027, but a roughly 15 percent cut to hundreds of tests looms without permanent reform), and private-payer pricing pressure caps growth. Labor shortages in clinical lab technologists and molecular specialists can raise costs and constrain capacity. Increased FDA oversight of laboratory-developed tests could add compliance burden. Acquisition-led growth carries integration and overpayment risk, and a large debt load from deal activity adds interest expense. Finally, the business is competitive and partly commoditized, so share losses to Labcorp, hospital in-sourcing, or specialty labs would pressure both volume and margin.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Quest Diagnostics Incorporated's investor relations page or your broker.

• Revenue (TTM): ~$11.5B
• 2026 revenue guidance: ~$11.78B to $11.9B
• 2026 adj. EPS guidance: ~$10.63 to $10.83
• Market cap: ~$22.8B
• P/E (trailing / forward): ~22.8x / ~19.2x
• Dividend (annual / yield): ~$3.44 / ~1.6%

In Q1 2026 Quest reported revenue of about $2.9 billion (up 9.2 percent) and adjusted EPS of $2.50 (up 13.1 percent), and raised full-year guidance. The stock traded near $205 in mid-July 2026 at a forward P/E under 20, a moderate multiple below primary competitor Labcorp. The dividend has risen for 15 consecutive years, most recently a 7.5 percent increase.

There are three common ways to get DGX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so DGX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where DGX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

DGX is a large-cap, dividend-raising lab-testing leader whose story hinges on steady volume growth, tuck-in acquisitions, and a mix shift toward advanced diagnostics, balanced against reimbursement policy risk.

Whether DGX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DGX a buy?, and where the stock could go from here in the DGX stock forecast.

For income investors, whether DGX pays a dividend and how the payout looks is covered in does DGX pay a dividend?